European Sustainable Bio-based nanoMAterials Community
BIOMAC
Innovation action 952941
Coordinator
Aristotle University of Thessaloniki, prof. Dimitrios Bikiaris
Duration
1/1/2021-31/12/2024
Overall budget
€ 16 596 702,50
​
​
Objective
Recent developments render the biobased sector a key player in European Economy providing a great impetus towards Circular Business Models of resource efficiency. Developments in biobased nanomaterials are coupled with biotechnologies applied to biomass converting the renewable resources into high added-value polymers. BIOMAC will establish an Open Innovation Test Bed (OITB) Ecosystem providing open access to SMEs or Industry to a single-entry point. Starting from the utilization of biomass sources followed by the production of biobased nanoparticles and different building blocks the ecosystem produces biopolymers
Website
www.biomac-oitb.eu
Contact
biomac@chem.auth.gr
for the strategic sectors of Food Packaging, Construction, Automotive and Printed Electronics which consist a high market share. A self-sustainable open innovation ecosystem for the upscaling of upscaled processes across the supply and value chain is intended to be created in order fill this gap. Although the last two decades a large number of publications have emerged, a very limited number of such cases has been finally commercialized and reached the market end users. Some of the reasons that these have not been adopted by the market are lack of investment, funding for further development, upscaling and the limited willingness of end users to adopt nanomaterials into their processes, this is the ‘valley of death’ which BIOMAC intends to overcome.The OITB will offer services that cover the assessment of regulation & safety, sustainability, circularity and market potential among others with modeling, process control, standardization and characterization; accessible at fair conditions and cost. BIOMAC establishes a concrete community of open collaboration for stakeholders and customers enabling innovation and minimization of investment risks. This will be achieved by offering an open innovation ecosystem, in which technologies that have been developed up to TRL4-5 will be able to be upscaled and validated up to TRL 7.
​
Follow BIOMAC on social media
Further reading